These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24375440)

  • 101. Airway epithelial SPDEF integrates goblet cell differentiation and pulmonary Th2 inflammation.
    Rajavelu P; Chen G; Xu Y; Kitzmiller JA; Korfhagen TR; Whitsett JA
    J Clin Invest; 2015 May; 125(5):2021-31. PubMed ID: 25866971
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
    McKiernan J; Noerholm M; Tadigotla V; Kumar S; Torkler P; Sant G; Alter J; Donovan MJ; Skog J
    BMC Urol; 2020 Sep; 20(1):138. PubMed ID: 32873277
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Prostate-Derived ETS Factor (PDEF) Modulates Yes Associated Protein 1 (YAP1) in Prostate Cancer Cells: A Potential Cross-Talk between PDEF and Hippo Signaling.
    Jaiswal PK; Mohajan S; Koul S; Wang F; Shi R; Koul HK
    Pharmaceuticals (Basel); 2019 Dec; 12(4):. PubMed ID: 31835563
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanisms.
    Emami NC; Kachuri L; Meyers TJ; Das R; Hoffman JD; Hoffmann TJ; Hu D; Shan J; Feng FY; Ziv E; Van Den Eeden SK; Witte JS
    Nat Commun; 2019 Jul; 10(1):3107. PubMed ID: 31308362
    [TBL] [Abstract][Full Text] [Related]  

  • 105. The androgen-induced protein AIbZIP facilitates proliferation of prostate cancer cells through downregulation of p21 expression.
    Cui X; Cui M; Asada R; Kanemoto S; Saito A; Matsuhisa K; Kaneko M; Imaizumi K
    Sci Rep; 2016 Nov; 6():37310. PubMed ID: 27853318
    [TBL] [Abstract][Full Text] [Related]  

  • 106. GADD45α and γ interaction with CDK11p58 regulates SPDEF protein stability and SPDEF-mediated effects on cancer cell migration.
    Tamura RE; Paccez JD; Duncan KC; Morale MG; Simabuco FM; Dillon S; Correa RG; Gu X; Libermann TA; Zerbini LF
    Oncotarget; 2016 Mar; 7(12):13865-79. PubMed ID: 26885618
    [TBL] [Abstract][Full Text] [Related]  

  • 107. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result.
    Donovan MJ; Noerholm M; Bentink S; Belzer S; Skog J; O'Neill V; Cochran JS; Brown GA
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):370-5. PubMed ID: 26345389
    [TBL] [Abstract][Full Text] [Related]  

  • 108. SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.
    Cheng XH; Black M; Ustiyan V; Le T; Fulford L; Sridharan A; Medvedovic M; Kalinichenko VV; Whitsett JA; Kalin TV
    PLoS Genet; 2014 Sep; 10(9):e1004656. PubMed ID: 25254494
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
    Wirth MP; Hakenberg OW; Froehner M
    Front Radiat Ther Oncol; 2008; 41():39-48. PubMed ID: 18544984
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Hormone therapy for radiorecurrent prostate cancer.
    Payne H; Khan A; Chowdhury S; Davda R
    World J Urol; 2013 Dec; 31(6):1333-8. PubMed ID: 22996761
    [TBL] [Abstract][Full Text] [Related]  

  • 111. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.
    Haller AC; Tan W; Payne-Ondracek R; Underwood W; Tian L; Morrison C; Li F
    Prostate; 2014 May; 74(5):509-19. PubMed ID: 24375440
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
    Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
    Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
    Kitagawa Y; Hinotsu S; Shigehara K; Nakashima K; Kawaguchi S; Yaegashi H; Mizokami A; Akaza H; Namiki M
    Int J Urol; 2013 Jul; 20(7):708-14. PubMed ID: 23216462
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
    N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.
    Xu M; Sakamoto S; Matsushima J; Kimura T; Ueda T; Mizokami A; Kanai Y; Ichikawa T
    J Urol; 2016 May; 195(5):1588-1597. PubMed ID: 26682754
    [TBL] [Abstract][Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.